| Non-Autoinflammatory diseases(n=1545) | Autoinflammatory diseases (n=117) | |
| Age (years) | ||
| Mean±SD | 54.7±17.5 | 38.7±20.5 |
| <18 | 41/1545 (2.7) | 17/117 (14.5) |
| 18–54 | 700/1545 (45.3) | 74/117 (63.2) |
| 55–64 | 328/1545 (21.2) | 8/117 (6.8) |
| 65–74 | 260/1545 (16.8) | 9/117 (7.7) |
| ≥75 | 216/1545 (14.0) | 9/117 (7.7) |
| Female gender | 1038/1545 (67.2) | 64/117 (54.7) |
| Comorbidities | ||
| Respiratory disease | 204/1543 (13.2) | 6/117 (5.1) |
| Interstitial lung disease | 60/1543 (3.9) | 0/117 (0.0) |
| COPD | 61/1543 (4.0) | 2/117 (1.7) |
| Asthma | 95/1543 (6.2) | 4/117 (3.4) |
| Cardiovascular disease | 177/1543 (11.5) | 11/117 (9.4) |
| Coronary heart diseases | 146/1543 (9.5) | 9/117 (7.7) |
| Stroke | 42/1543 (2.7) | 5/117 (4.3) |
| Diabetes | 156/1543 (10.1) | 8/117 (6.8) |
| BMI (kg/m²) | 26.0 (22.0 ; 29.0) | 23.0 (21.0 ; 26.0) |
| <30 | 1054/1388 (75.9) | 98/111 (88.3) |
| 30–39.9 | 297/1388 (21.4) | 10/111 (9.0) |
| ≥40 | 37/1388 (2.7) | 3/111 (2.7) |
| Hypertension | 361/1543 (23.4) | 12/117 (10.3) |
| Cancer | 57/1543 (3.7) | 3/117 (2.6) |
| Smoking | 139/1543 (9.0) | 8/117 (6.8) |
| Chronic renal failure | 80/1543 (5.2) | 5/117 (4.3) |
| Number comorbidities | ||
| 0 | 674/1543 (43.7) | 76/117 (65.0) |
| 1 | 466/1543 (30.2) | 26/117 (22.2) |
| 2 | 230/1543 (14.9) | 8/117 (6.8) |
| 3 | 103/1543 (6.7) | 4/117 (3.4) |
| 4 | 58/1543 (3.8) | 3/117 (2.6) |
| >4 | 12/1543 (0.8) | 0/117 (0.0) |
| Rheumatic or inflammatory Diseases treatments | ||
| Corticosteroid | 460/1542 (29.8) | 20/117 (17.1) |
| Systemic corticosteroid doses≥10 mg/day | 176/458 (38.4) | 6/20 (30.0) |
| NSSAIDs | 147/1542 (9.5) | 2/117 (1.7) |
| Colchicine | 10/1542 (0.6) | 72/117 (61.5) |
| Hydroxychloroquine | 146/1542 (9.5) | 0/117 (0.0) |
| Methotrexate | 553/1542 (35.9) | 13/117 (11.1) |
| Leflunomide | 66/1542 (4.3) | 0/117 (0.0) |
| Salazopyrine | 17/1542 (1.1) | 0/117 (0.0) |
| Mycophenolate Mofetil /mycophenolic acid | 41/1542 (2.7) | 0/117 (0.0) |
| Azathioprine | 18/1542 (1.2) | 4/117 (3.4) |
| IgIV | 10/1542 (0.6) | 0/117 (0.0) |
| Targeted biologic or synthetic therapies | ||
| anti-TNF | 469/1542 (30.4) | 18/117 (15.4) |
| anti-IL6R | 56/1542 (3.6) | 5/117 (4.3) |
| anti-IL17A | 51/1542 (3.3) | 0/117 (0.0) |
| anti-IL1 | 2/1542 (0.1) | 12/117 (10.3) |
| abatacept | 34/1542 (2.2) | 1/117 (0.9) |
| JAK inhibitor | 56/1542 (3.6) | 1/117 (0.9) |
| Rituximab | 83/1542 (5.4) | 0/117 (0.0) |
| Other biologics | 33/1542 (2.1) | 1/117 (0.9) |
Values are presented as no./total no. (%) unless otherwise indicated
COPD, Chronic obstructive pneumopathy disease; IgIV, Intravenous immunoglobulins.